SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
1st Jul 20107:00 amRNSDirector/PDMR Shareholding
28th Jun 201010:52 amRNSDirector/PDMR Shareholding
8th Jun 20104:01 pmRNSDirector/PDMR Shareholding
7th Jun 20105:15 pmRNSDirector/PDMR Shareholding
2nd Jun 20103:23 pmRNSDirector/PDMR Shareholding
2nd Jun 20107:00 amRNSDirectorate Change
19th Mar 20107:00 amRNSDirector/PDMR Shareholding
8th Mar 20107:00 amRNSHalf Yearly Report
25th Feb 20107:00 amRNSChange of Adviser
15th Dec 200912:03 pmRNSAGM Statement
4th Dec 20097:00 amRNSDirector/PDMR Shareholding
25th Nov 200910:35 amRNSGeneral Meeting
9th Nov 20097:00 amRNSPlacing and Notice of General Meeting
28th Oct 20099:14 amRNSDividend
13th Oct 20098:35 amRNSGrant of options
12th Oct 20097:00 amRNSFinal Results
18th Sep 20097:00 amRNSLicensing agreement
3rd Jul 200911:28 amRNSDirectors' Dealing
3rd Jul 20097:00 amRNSAcquisition and Placing
11th May 20097:00 amRNSExclusive UK distribution agreement
17th Mar 20099:35 amRNSCorrection to Record Date
16th Mar 20097:00 amRNSHalf Yearly Report
9th Mar 20097:00 amRNSNew infection control range for dental practices
8th Jan 20097:00 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSAGM Statement
7th Nov 20087:00 amRNSNHS Supply Chain listing
6th Oct 20087:00 amRNSFinal Results
3rd Sep 20089:05 amRNSGrant of Patent
25th Jul 20087:00 amRNSTrading update & Notice of re
7th Jul 200810:55 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSGrant of Patent
23rd Jun 20087:00 amRNSSupply and Distribution Agree
28th May 200811:32 amRNSDirector/PDMR Shareholding
2nd May 20087:00 amRNSDirector/PDMR Shareholding
4th Apr 20085:04 pmRNSCorrection -Board Appointment
4th Apr 20087:01 amRNSDirector/PDMR Shareholding
3rd Apr 20087:00 amRNSBoard Appointment
27th Mar 20089:26 amRNSDirector/PDMR Shareholding
12th Mar 20081:30 pmRNSIssue of Equity
3rd Mar 20087:01 amRNSNew supply agreement
3rd Mar 20087:00 amRNSInterim Results
7th Feb 20087:00 amRNSNotice of Results
6th Feb 20081:19 pmRNSRe. Tristel Italia srl
3rd Jan 20083:29 pmRNSGrant of patent
11th Dec 200711:42 amRNSAGM Statement
5th Nov 200712:38 pmRNSDirector/PDMR Shareholding
29th Oct 20071:01 pmRNSDividend
29th Oct 20077:01 amRNSFinal Results
16th Oct 20077:00 amRNSChange of Adviser
8th Oct 20077:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.